Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $8.0 million.

  • Stoke Therapeutics' Share-based Compensation rose 7.27% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.6 million, marking a year-over-year increase of 11.83%. This contributed to the annual value of $27.5 million for FY2024, which is 8.70% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Share-based Compensation stood at $8.0 million, which was up 5.80% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Share-based Compensation registered a high of $8.0 million during Q3 2025, and its lowest value of $5.0 million during Q1 2022.
  • For the 3-year period, Stoke Therapeutics' Share-based Compensation averaged around $6.8 million, with its median value being $6.8 million (2023).
  • As far as peak fluctuations go, Stoke Therapeutics' Share-based Compensation declined by 8.10% in 2024, and later increased by 24.82% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Share-based Compensation (Quarterly) stood at $5.8 million in 2022, then increased by 4.54% to $6.1 million in 2023, then grew by 17.51% to $7.2 million in 2024, then increased by 7.27% to $8.0 million in 2025.
  • Its Share-based Compensation stands at $8.0 million for Q3 2025, versus $7.6 million for Q2 2025 and $6.8 million for Q1 2025.